Skip to content
value.today

Zymeworks Inc.: valuation

What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.

Cash-flow value

Free cash flow over the last three years averaged below zero, so a cash-flow value cannot be worked out.

Price to salesPrice to sales of Biotechnology: $236 M to $1.0 B, median $521 MPrice to bookPrice to book of Biotechnology: $822 M to $3.5 B, median $1.2 B$0 M$934 M$1.9 B$2.8 B$3.7 BMarket value $2.0 B

Your own DCF model

A full discounted-cash-flow model of Zymeworks Inc., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.

Open the DCF model

Against the industry Biotechnology

Multiples of its companies with a market value at most 60 days old, times Zymeworks Inc.'s own figures of FY2025.

Values from the peers' multiples
MultiplePeers (25th / median / 75th)Zymeworks Inc.Applied toValue (25th to 75th)Companies
Price to sales2.2× / 4.9× / 9.9×18.8×revenue $106 M$236 M to $1.0 B84
Price to book3.1× / 4.5× / 12.9×7.4×book equity $269 M$822 M to $3.5 B69

Peers' multiples from the distributions by industry; the company's figures from its statements below. A multiple says what similar companies cost, not what this one is worth.

Against its own history

Zymeworks Inc.'s multiples at each month end with a market cap on file, Jan 2022 to Oct 2026, each against its own median.

Price to sales

53.7×

Now above its median of 15.6×, in the top quarter of its range; range 1.1× to 53.7× over 28 months.

0×13×27×40×54×2023202420252026Price to sales 54×Median 16×

Price to book

7.4×

Now above its median of 3.5×, in the top quarter of its range; range 0.9× to 7.5× over 28 months.

0×2×4×6×8×2023202420252026Price to book 7×Median 3×

as of Oct 29, 2026. Market caps: the dated values on file since 2020, and in between the SEC's fails-to-deliver closing price times the share count on the latest 10-K or 10-Q cover. Each month divides by the last twelve months' results that had been published by then (a quarter 45 days after it ended, a fiscal year 60 days after), so the past is not read with figures that came out later; months with a loss give no P/E. Newest month: Oct 29, 2026.

The statements it starts from

USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.

Figures from the annual statements
Fiscal yearRevenueNet incomeCash from operationsCapital spendingFree cash flowNet debtSource
FY2025to Dec 31, 2025$106 M$-81 M$-33 M$2 M$-35 M—SEC annual report (10-K, 20-F)
FY2024to Dec 31, 2024$76 M$-123 M$-110 M$2 M$-112 M—SEC annual report (10-K, 20-F)
FY2023to Dec 31, 2023$76 M$-119 M$-118 M$2 M$-121 M—SEC annual report (10-K, 20-F)
FY2022to Dec 31, 2022$412 M$124 M$144 M$8 M$136 M—SEC annual report (10-K, 20-F)
FY2021to Dec 31, 2021$27 M$-212 M$-192 M$12 M$-205 M—SEC annual report (10-K, 20-F)
FY2020to Dec 31, 2020$39 M$-181 M$-151 M$4 M$-156 M—SEC annual report (10-K, 20-F)

Each figure as filed; the full statements with every line and its filing are on the company page. Market value $2.0 B on Oct 29, 2026.

How it is worked out: the cash-flow value is free cash flow grown at the first-stage rate for the years chosen, then at the long-run rate for ever, each year discounted at the risk-free rate plus the equity risk premium, less net debt. What the price assumes is the first-stage growth that makes that value equal today's market value. The starting cash flow, growth and net debt come from the statements; the risk-free rate from the US Treasury; the premium and the long-run growth are assumptions and are labelled so. This is arithmetic on reported figures, not advice.